Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interview: KaNDy Menopause Therapy Hits Sweet Spot

NT-814 Set For Phase III Trials

Executive Summary

Prospective partners will be impressed by data which shows that the UK company's once-daily oral treatment reduces hot flashes and night sweats and has also shown very rapid improvements in mood and sleep.

You may also be interested in...



GSK Spin-Off Launches KaNDy To Tackle Key Symptoms Of Menopause

NeRRe Therapeutics has set up a new entity around a drug which it believes could be an effective alternative to hormone replacement therapy for hot flashes that may rapidly reduce debilitating sleep disturbance.

AZ Closer To Second Enhertu OK After Gastric Cancer Success

The Daiichi Sankyo-partnered antibody drug conjugate has just been approved for breast cancer and AstraZeneca's oncology R&D chief tells Scrip that there are many other HER-2-expressing tumor types where Enhertu has shown potential.

J&J's Stelara Gets Europe OK For Pediatric Psoriasis

The European Commission has backed J&J's blockbuster to treat children with psoriasis but the drug has fallen foul of NICE for ulcerative colitis.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141461

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel